Teladoc Health (NYSE:TDOC) Updates FY 2025 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of -1.100–0.500 for the period, compared to the consensus estimate of -1.030. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q1 2025 guidance to -0.400–0.150 EPS.

Teladoc Health Price Performance

Shares of NYSE:TDOC traded down $0.21 during trading on Friday, reaching $9.29. The company had a trading volume of 3,940,371 shares, compared to its average volume of 8,266,508. The company has a fifty day moving average of $10.62 and a two-hundred day moving average of $9.53. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $1.60 billion, a P/E ratio of -1.61 and a beta of 1.04. Teladoc Health has a 12 month low of $6.76 and a 12 month high of $15.95.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The firm had revenue of $640.49 million during the quarter, compared to the consensus estimate of $639.44 million. Equities research analysts forecast that Teladoc Health will post -1.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TDOC has been the subject of several research reports. Deutsche Bank Aktiengesellschaft upped their target price on Teladoc Health from $10.00 to $12.00 and gave the stock a “hold” rating in a research note on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Teladoc Health in a research report on Thursday. Oppenheimer lowered their price target on shares of Teladoc Health from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, January 24th. TD Cowen reduced their price objective on Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Thursday, October 31st. Finally, Royal Bank of Canada boosted their target price on Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Eleven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.44.

Insider Buying and Selling

In other Teladoc Health news, insider Carlos Nueno sold 2,389 shares of Teladoc Health stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $11.93, for a total value of $28,500.77. Following the completion of the transaction, the insider now directly owns 2,890 shares of the company’s stock, valued at approximately $34,477.70. The trade was a 45.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is owned by company insiders.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.